1. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M. Wojdyla, Cheryl D. Bushnell, Michael Hanna, J. Donald Easton, Laine Thomas, Lars Wallentin, Sana M. Al-Khatib, Claes Held, Pedro Gabriel Melo de Barros e Silva, John H. Alexander, Christopher B. Granger, and Hans-Christoph Diener
Blood
Volume 129(22):
June 1, 2017
©2017 by American Society of Hematology

2. Rates of ICH by location, type, and randomized treatment.
Rates of ICH by location, type, and randomized treatment. The benefits of apixaban over warfarin in causing significantly less ICH was consistent regardless of type and location of ICH.
Renato D. Lopes et al. Blood 2017;129:
©2017 by American Society of Hematology

3. Thirty-day all-cause mortality after ICH event by randomized treatment.
Thirty-day all-cause mortality after ICH event by randomized treatment. Similar rates of all-cause mortality following ICH were observed in apixaban- and warfarin-treated patients.
Renato D. Lopes et al. Blood 2017;129:
©2017 by American Society of Hematology